MCRB - Seres Therapeutics, Inc.
IEX Last Trade
0.8706
-0.005 -0.563%
Share volume: 5,085
Last Updated: Fri 27 Dec 2024 08:27:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.88
0.00
-0.56%
Fundamental analysis
25%
Profitability
18%
Dept financing
25%
Liquidity
46%
Performance
27%
Performance
5 Days
-4.25%
1 Month
0.99%
3 Months
0.57%
6 Months
16.97%
1 Year
-34.46%
2 Year
-81.84%
Key data
Stock price
$0.87
DAY RANGE
$0.87 - $0.91
52 WEEK RANGE
$0.60 - $2.05
52 WEEK CHANGE
-$33.99
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Eric D. Shaff
Region: US
Website: serestherapeutics.com
Employees: 330
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: serestherapeutics.com
Employees: 330
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Seres Therapeutics, Inc. engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection. SER-155, a cultivated bacteria microbiome drug, is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases.
Recent news